Skip to content

Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03153566
Enrollment
45
Registered
2017-05-15
Start date
2017-06-01
Completion date
2018-12-31
Last updated
2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital Wart

Brief summary

Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.

Detailed description

Genital warts are highly contagious sexually transmitted diseases (STD) caused by infection of Human Papilloma Virus and, as the most common STD in developed countries, can currently be considered to be globally epidemic. It is estimated that the frequency of Human Papilloma Virus infection among women in the world ranges from 2% to 44%. The conventional modalities in treatment of warts include destructive therapies such as salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, cantharidin, surgical interventions and laser, antiproliferative agents such as bleomycin, vitamin D analogs, podophyllin, 5 fluorouracil and antiviral agents such as cidofovir and retinoids. There are different mechanisms have been proposed for the resolution of warts with skin test antigens such as mumps, candida, trichophyton both at the injected as well as distant sites. Tuberculin: Purified protein derivative or tuberculin stimulates the cell mediated immunity non specifically by activating T helper 1 cells, Natural Killer cells, and cytokine production an increase in interleukin-12 as a process in boosting the cell-mediated immunity contributes to the mechanism of action.

Interventions

BIOLOGICALtuberculin

inject the mother wart with .3 ml tuberculin vaccine every 2 weeks

DEVICEcryotherapy

10 sec 1 cycle into all genital warts

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* All types of genital and anal warts will be included in this study especially patients with 5 or more warts and more than 1 cm in size

Exclusion criteria

* Patients with immunodeficient diseases or receiving any immunosuppressive drugs * Pregnancy and lactation

Design outcomes

Primary

MeasureTime frameDescription
number of patients with complete resolution of genital warts4 monthsfrequency (number)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026